Literature DB >> 15211958

Endovascular treatment of intractable epistaxis--results of a 4-year local audit.

I C Duncan, P A Fourie, C E le Grange, H A van der Walt.   

Abstract

OBJECTIVE: Transcatheter embolisation is an accepted and effective treatment for intractable epistaxis. We analysed our success and complication rates and compared these with results from other published series.
DESIGN: Retrospective review.
SETTING: Unitas Interventional Unit, Centurion.
METHODS: Case record review (57 procedures) and telephonic interviews (36 traceable respondents). OUTCOME MEASURES: A numerical audit of the success and complication rates for embolisation procedures performed during the 4-year period between July 1999 and June 2003.
RESULTS: A total of 57 endovascular embolisation procedures were performed for intractable epistaxis in 51 patients during this period. Eight patients (15.7%) developed a re-bleed between 1 and 33 days after embolisation, of whom 5 were reembolised, giving a primary short-term success rate of 86.3% and secondary assisted success rate of 94.1%. Thirty-five of 36 respondents (97.2%) reported no further epistaxis during the long-term follow-up period of 1-47 months. The mortality rate was 0%, the major morbidity rate was 2% (1 stroke) and the minor morbidity rate was 25%.
CONCLUSION: Our success and complication rates are acceptable and compare favourably with those reported in other large series.

Entities:  

Mesh:

Year:  2004        PMID: 15211958     DOI: 10.4102/sajr.v8i3.118

Source DB:  PubMed          Journal:  S Afr Med J


  9 in total

1.  Transarterial endovascular treatment in the management of life-threatening intra- and postoperative haemorrhages after otorhinolaryngological surgery.

Authors:  Andreas Schrock; Mark Jakob; Katharina Strach; Benjamin Pump; Andreas Otto Gerstner; Kai Wilhelm; Horst Urbach; Friedrich Bootz; Susanne Greschus
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-11-12       Impact factor: 2.503

Review 2.  Transcatheter embolization in the management of epistaxis.

Authors:  Gregory J Dubel; Sun Ho Ahn; Gregory M Soares
Journal:  Semin Intervent Radiol       Date:  2013-09       Impact factor: 1.513

3.  Comparison of microporous polysaccharide hemospheres and Ankaferd Blood Stopper in a rabbit epistaxis model.

Authors:  Veysel Yurttas; Murat Sereflican; Elçin Hakan Terzi; Gulzade Ozyalvaçlı; Hasan Kazaz
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-06-23       Impact factor: 2.503

4.  Prospective, randomized, controlled clinical trial of Ankaferd Blood Stopper in patients with acute anterior epistaxis.

Authors:  Aysenur Meric Teker; Arzu Yasemin Korkut; Volkan Kahya; Orhan Gedikli
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-02-13       Impact factor: 2.503

5.  Superselective microcoil embolization in severe intractable epistaxis: an analysis of 12 consecutive cases from an otorhinolaryngologic and an interventional neuroradiologic point of view.

Authors:  D U Seidel; S Remmert; F Brassel; M Schlunz-Hendann; D Meila
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-12-11       Impact factor: 2.503

6.  Outcomes after endovascular embolization for the treatment of nasal and oropharyngeal hemorrhage: safety, efficacy, and rebleeding.

Authors:  Haydn Hoffman; Muhammad S Jalal; Hesham E Masoud; Grahame C Gould
Journal:  Neuroradiol J       Date:  2021-09-03

Review 7.  Assessment of safety and efficacy of arterial embolisation in the management of intractable epistaxis.

Authors:  Maziar Sadri; Katie Midwinter; Aftab Ahmed; Andrew Parker
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-02-21       Impact factor: 2.503

8.  Embolization for the treatment of intractable epistaxis: 12 month outcomes in a two centre case series.

Authors:  Anthony E Robinson; William McAuliffe; Timothy J Phillips; Constantine C Phatouros; Tejinder P Singh
Journal:  Br J Radiol       Date:  2017-10-26       Impact factor: 3.039

9.  Endovascular treatment of a giant aneurysm of the maxillary artery.

Authors:  J A Stephenson; S Panteleimonitis; E Choke; M Dennis; M Glasby
Journal:  Case Rep Vasc Med       Date:  2012-01-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.